Good News for ITP Patients: Ianalumab + Eltrombopag Prolongs Time to Treatment Failure VS Eltrombopag Alone
Roger Schutgens, Professor of Thrombosis and Haemostasis at UMC Utrecht, shared on LinkedIn:
“Good news for patients with ITP.
Recently, the results of the VAYHIT2 trial have been published in The New England Journal of Medicine, showing that a course of B-cell–targeted therapy (ianalumab) combined with eltrombopag significantly prolongs time to treatment failure compared to eltrombopag alone in adults with immune thrombocytopenia after first-line steroids (13 months versus 4.7 months).
More patients were able to taper and discontinue eltrombopag (62% versus 39%), supporting the concept of early, disease-modifying treatment in ITP.
It was a joyfull ride to be part of this endeavor.”
Title: Ianalumab plus Eltrombopag in Immune Thrombocytopenia
Authors: Adam Cuker, Thomas Stauch, Nichola Cooper et al.
Read the full article.
Hemostasis Today has more posts you may find interesting.
-
Jul 18, 2026, 21:05Federica Fedele: From One-Size-Fits-All to Personalized Care
-
Jul 18, 2026, 21:04Sandra RodrÃguez Coma: A Great Experience With the Werfen Team at ISTH 2026
-
Jul 18, 2026, 20:58Heghine Khachatryan: Cancer-Associated ATE – An Underrecognized Challenge in Modern Oncology
-
Jul 18, 2026, 20:57Barbara Adams Krolak: The Science Was Even Hotter Than Paris
-
Jul 18, 2026, 20:15Ahmed Kotb: Exploring Qualitative Platelet Defects
-
Jul 18, 2026, 20:08Bianca Heidersdorf: Shaping the Future of Bleeding Disorders Support at ISTH 2026
-
Jul 18, 2026, 18:00Karen Schreiber: Advancing Thrombosis Epidemiology Through Global Collaboration at ISTH 2026
-
Jul 18, 2026, 17:34Living With ITP – A New Resource for Navigating Your Diagnosis – ITP Support Association
-
Jul 18, 2026, 17:34Mona Alfaraj: It Was a Hot Week Attending ISTH 2026 Congress in Paris